Alabama Litigation Review

Alabama Litigation Review

Insights & Commentary on Developments in Alabama Litigation

Tag Archives: drug

Does The Drug Abilify Cause Compulsive Behaviors?

Posted in Defective Products
It’s difficult to believe. Like many people, I had serious doubts. Very serious doubts. Can a drug really cause compulsive behaviors like uncontrollable gambling? Many Abilify victims suffered the doubts of family and friends. Yet, new medical research now supports a link between the drug and these dangerous compulsive behaviors. WHAT IS ABILIFY? The Food… Continue Reading

New Anticoagulants Continue To Raise Safety Issues

Posted in Defective Products, Personal Injury
In September, I discussed new anticoagulants Xarelto and Eliquis. My prior post concludes by noting patients deserve drugs approved only after careful study for safety. Shortly after that post, the ISMP Quarterwatch also raised issues concerning the safety of new anticoagulants rivaroxaban (Xarelto), dabigatron (Pradaxa), and apixaban (Eliquis). According to Quarterwatch: The adverse event reports for oral… Continue Reading

Invokana And The Risk Of Bone Fractures

Posted in Defective Products
Is Invokana (canagliflozin) a dangerous and defective drug? In a prior post, I discussed the history of Invokana and its link to ketoacidosis. Ketoacidosis can be a life-threatening condition caused by a build-up of acid in the blood. Now, the FDA has issued a new Invokana safety warning. According to the new FDA safety alert:… Continue Reading

First Pradaxa. Then Xarelto. Now Eliquis?

Posted in Defective Products, Personal Injury
Will Eliquis join Pradaxa and Xarelto as another anti-coagulant drug facing claims of severe internal bleeding? Pradaxa was the first of these three new anti-coagulants (blood thinners). It hit the market in 2010. Sales quickly boomed. However, adverse reports of severe internal hemorrhaging and bleeding soon followed. In May 2014, Pradaxa’s manufacturer settled about 4,000… Continue Reading

Invokana – Is The Drug A Safe Treatment For Diabetes?

Posted in Defective Products, Personal Injury
Invokana (canagliflozin) is a relatively new drug marketed to treat Type 2 diabetes. The drug is the first in a new class of medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. This class of drugs also includes Farxiga, Glyxambi, Jardiance, and Xigduo XR. How does this new class of drugs work? The drugs work by altering… Continue Reading

Were Clinical Trials For Xarelto Tainted By Misconduct?

Posted in Defective Products, Personal Injury
What is Xarelto? Xarelto (Rivaroxaban) is a relatively new anticoagulant (blood thinner). The FDA first approved Xarelto in 2011. It is distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Healthcare. Xarelto was released as a replacement for Coumadin (Warfarin), a blood thinner effectively used for decades. Xarelto is used… Continue Reading

Boston Scientific Suffers Another Trial Loss Over A Mesh Product

Posted in Defective Products, Federal Courts, Personal Injury
Last week, a Federal Court jury in Florida found Boston Scientific liable for the severe personal injuries caused by one of its transvaginal mesh products. The Florida case involved four women suffering tremendous problems from implanted mesh. The jury assessed $26.7 Million in damages against the company. This was not the first trial loss suffered by… Continue Reading

Workers’ Compensation And The Alabama Pain Management Act

Posted in Workers' Compensation
I often enjoy reading posts from the Alabama Workers Comp Blawg. While good attorneys, their approach is only from the defense side. That is quite different from my practice handling plaintiffs’ personal injury and workers’ compensation cases. So, while informative, I often disagree with their position. Recently, these defense attorneys wrote about the new Alabama… Continue Reading

Update: Injured By A Defective Generic Drug? Where Is The Justice?

Posted in Defective Products
In August, I wrote about the recent Supreme Court decisions shielding generic drug makers from accountability for injuries and deaths caused by their defective drugs. Because generic drug makers were required to use the same warning label as the brand name manufacturer, they were provided immunity for failing to warn of dangerous side effects. This… Continue Reading

Defective Drugs And Research Bias

Posted in Defective Products
We are presently representing clients who have been injured by several different defective medical products, including the diabetes drug Actos and transvaginal mesh. As part of our work, we have studied much of the available medical research. Recently, I viewed an interesting discussion on an issue important in the medical research. The issue is: Why are… Continue Reading

Alabama Will Receive Share of Record Drug Company Fine

Posted in Defective Products, Personal Injury
Drug maker GlaxoSmithKline (Glaxo) will pay a record $3 Billion criminal fraud settlement with the government as a result of its deceptive sales practices. The criminal charges accused Glaxo of practices which pushed dangerous medications on the American public. According to the news, the State of Alabama will receive almost $6 Million of the proceeds.… Continue Reading

Whistleblower Files Suit Against Takeda Over Actos

Posted in Defective Products
Actos litigation is a subject that I have addressed on several occasions. The pending claims continue to move forward. As they progress, we learn more about the manufacturer Takeda’s research and marketing of this diabetes drug to the public. Last week, Bloomberg revealed that a whistleblower has also filed suit against Actos manufacturer Takeda. Add… Continue Reading

Actos Update – MDL Panel Consolidates Cases

Posted in Defective Products
The Federal Judicial Panel on Multidistrict Litigation has issued its Order consolidating all pending Actos cases in Federal Court. The cases have been consolidated before U.S. District Judge Rebecca Doherty in the U.S. District Court for the Western District of Louisiana. This means that Judge Doherty will preside over all the pretrial proceedings in these… Continue Reading

Type 2 Diabetes, Actos, and Bladder Cancer

Posted in Defective Products
Many adults are impacted by Type 2 diabetes (sometimes referred to as adult-onset diabetes or non insulin-dependent diabetes).  Type 2 diabetes is a chronic condition that affects the way your body metabolizes sugar.  Left untreated it can be life-threatening.  However, the condition can be managed.  Often, it can be managed through diet and exercise.  Unfortunately,… Continue Reading

Can the Heart Medication MULTAQ Cause Severe Liver Injury

Posted in Defective Products
Atrial fibrillation is a huge health issue affecting many individuals.  It is estimated that this condition affects 2.3 million Americans.  At present, the FDA has approved a variety of treatments. In 2009, the drug company Sanofi-Aventis began to market dronedarone under the brand name Multaq as an additional medication for atrial fibrillation.  Although the FDA… Continue Reading

The Government Has A Record Year Seeking Justice For Wrongful Conduct by the Drug Industry

Posted in Defective Products
Yesterday, the United States Department of Justice announced that it had recovered $3 Billion in fiscal year 2010 against those companies and individuals who had defrauded our government.  These recoveries involved claims for all types of fraud against our government, including military contracts, non-military contracts, federally-insured mortgages, and mineral leases, among others.  It is a welcome… Continue Reading

Was the FDA Advisory Panel on Avandia Tainted by Conflict?

Posted in Defective Products
It’s been an eventful summer for GlaxoSmithKline (GSK) and its diabetes drug, Avandia.  First, the New York Times dropped its bombshell that secret company testing in 1999 indicated the increased risk of heart attacks associated with Avandia.  Yet, the company may have hidden its own test results, while reaping billions of dollars in revenue continuing… Continue Reading